Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016, Article ID 5302120, 5 pages
http://dx.doi.org/10.1155/2016/5302120
Research Article

Clinical Application of Autologous Adipose Stem Cells in Patients with Multiple Sclerosis: Preliminary Results

1Department of Neurology, Military Institute of Medicine, Warsaw, Poland
2Laboratory of Cellular Engineering, M. Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, 02-781 Warsaw, Poland
3Department of Breast Cancer and Reconstructive Surgery, Oncology Center-Institute, Warsaw, Poland
4Department of Radiology, Military Institute of Medicine, Warsaw, Poland
5Polish Academy of Sciences, Warsaw, Poland

Received 10 July 2016; Accepted 14 September 2016

Academic Editor: Nina Ivanovska

Copyright © 2016 Adam Stepien et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Pugliatti, G. Rosati, H. Carton et al., “The epidemiology of multiple sclerosis in Europe,” European Journal of Neurology, vol. 13, no. 7, pp. 700–722, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Kingwell, J. J. Marriott, N. Jetté et al., “Incidence and prevalence of multiple sclerosis in Europe: a systematic review,” BMC Neurology, vol. 13, no. 1, article 128, 2013. View at Publisher · View at Google Scholar
  3. S. V. Ramagopalan, J. C. Knight, and G. C. Ebers, “Multiple sclerosis and the major histocompatibility complex,” Current Opinion in Neurology, vol. 22, no. 3, pp. 219–225, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Boster, G. Edan, E. Frohman et al., “Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician,” The Lancet Neurology, vol. 7, no. 2, pp. 173–183, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Forostyak, A. Homola, K. Turnovcova, P. Svitil, P. Jendelova, and E. Sykova, “Intrathecal delivery of mesenchymal stromal cells protects the structure of altered Perineuronal nets in SOD1 rats and amends the course of ALS,” STEM CELLS, vol. 32, no. 12, pp. 3163–3172, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Constantin, S. Marconi, B. Rossi et al., “Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis,” Stem Cells, vol. 27, no. 10, pp. 2624–2635, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. M. W. Klinker and C. Wei, “Mesenchymal stem cells in the treatment of inflammatory and autoimmune diseases in experimental animal models,” World Journal of Stem Cells, vol. 7, no. 3, pp. 556–567, 2015. View at Publisher · View at Google Scholar
  8. R. Donders, M. Vanheusden, J. F. J. Bogie et al., “Human Wharton’s jelly-derived stem cells display immunomodulatory properties and transiently improve rat experimental autoimmune encephalomyelitis,” Cell Transplantation, vol. 24, no. 10, pp. 2077–2098, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. K. S. Kim, H. J. Lee, J. An et al., “Transplantation of human adipose tissue-derived stem cells delays clinical onset and prolongs life span in ALS mouse model,” Cell Transplantation, vol. 23, no. 12, pp. 1585–1597, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. A. C. Bowles, B. A. Scruggs, and B. A. Bunnell, “Mesenchymal stem cell-based therapy in a mouse model of Experimental Autoimmune Encephalomyelitis (EAE),” Methods in Molecular Biology, vol. 1213, pp. 303–319, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Fassas and R. Nash, “Multiple sclerosis,” Best Practice & Research: Clinical Haematology, vol. 17, no. 2, pp. 247–262, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. G. L. Mancardi, A. Murialdo, P. Rossi et al., “Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis,” Multiple Sclerosis, vol. 11, no. 3, pp. 367–371, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. G. L. Mancardi, M. P. Sormani, F. Gualandi et al., “Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial,” Neurology, vol. 84, no. 10, pp. 981–988, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Portaccio, M. P. Amato, G. Siracusa et al., “Autologous hematopoietic stem cell transplantation for very active relapsing-remitting multiple sclerosis: report of two cases,” Multiple Sclerosis, vol. 13, no. 5, pp. 676–678, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. V. K. Kimiskidis, I. Sakellari, V. Tsimourtou et al., “Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome,” Multiple Sclerosis, vol. 14, no. 2, pp. 278–283, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. V. Harris, T. Vyshkina, S. Chirls et al., Interim Analysis of a Phase I Clinical Trial Investigating Intrathecal Administration of Mesenchymal Stem Cell-Neural Progenitors in Multiple Sclerosis, Poster Session VII [P7.200], American Academy of Neurology, Washington, DC, USA, 2015.